



OHDSI OKR Mid-Year Review

OHDSI Community Call
June 1, 2021 • 11 am ET



Upcoming OHDSI Community Calls

Date	Topic
June 1	OHDSI OKR Mid-Year Review
June 8	10-Minute Tutorials: PHOEBE, Cohort Diagnostics, ATC Hierarchy
June 15	Professional Development Breakouts: Clinical Epidemiology, Information/Data Management, Open-Source Software Development, Statistical Methods
June 22	Community Presentations: New Developments within OHDSI
June 29	Focus Topic: EUMEAUS (Evaluating Use of Methods for Adverse Event Under Surveillance)
July 6	Meet & Greet New OHDSI Collaborators
July 13	Focus Topic: PROTEUS
July 20	Workgroup Updates
July 27	Visualization Challenge



Upcoming OHDSI Community Calls

Date	Topic
June 1	OHDSI OKR Mid-Year Review
June 8	10-Minute Tutorials: PHOEBE, Cohort Diagnostics, ATC Hierarchy
June 15	Professional Development Breakouts: Clinical Epidemiology, Information/Data Management, Open-Source Software Development, Statistical Methods
June 22	Community Presentations: New Developments within OHDSI
June 29	Focus Topic: EUMEAUS (Evaluating Use of Methods for Adverse Event Under Surveillance)
July 6	Meet OHDSI's Newest Collaborators
July 13	Focus Topic: PROTEUS
July 20	Workgroup Updates
July 27	Visualization Challenge



June 8: 10-Minute Tutorials



PHOEBE

Anna Ostropolets



Cohort Diagnostics

Gowtham Rao



ATC Hierarchy

Christian Reich



Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?






OHDSI Shoutouts!



Congratulations to **Talita Duarte-Salles, David Vizcaya, Andrea Pistillo, Paula Casajust, Anthony G. Sena, Lana Yin Hui Lai, Albert Prats-Urbe, Waheed-Ul-Rahman Ahmed, Thamir M Alshammari, Heba Alghoul, Osaid Alser, Edward Burn, Seng Chan You, Carlos Areia, Clair Blacketer, Scott DuVall, Thomas Falconer, Sergio Fernandez-Bertolin, Stephen Fortin, Asieh Golozar, Mengchun Gong, Eng Hooi Tan, Vojtech Huser, Pablo Iveli, Daniel R. Morales, Fredrik Nyberg, Jose D. Posada, Martina Recalde, Elena Roe, Lisa M. Schilling, Nigam H. Shah, Karishma Shah, Marc A. Suchard, Lin Zhang, Ying Zhang, Andrew E. Williams, Christian G. Reich, George Hripcsak, Peter Rijnbeek, Patrick Ryan, Kristin Kostka and Daniel Prieto-Alhambra** on this study published by Pediatrics: **30-day outcomes of Children and Adolescents with COVID-19: An International Experience.**



DOI: 10.1542/peds.2020-042929

Journal: *Pediatrics*

Article Type: Regular Article

Citation: Duarte-Salles T, Vizcaya D, Pistillo A, et al. 30-day outcomes of children and adolescents with COVID-19: an international experience. *Pediatrics*. 2021; doi: 10.1542/peds.2020-042929





OHDSI Shoutouts!



COVID-19 Updates Page

The Observational Health Data Sciences and Informatics (OHDSI) international community hosted a COVID-19 virtual study-a-thon March 26-29 to inform healthcare decision-making in response to the current global pandemic. That work served as the foundation for global community research into characterization, population-level effect estimation and patient-level prediction questions about the disease. Ongoing work continues in the OHDSI MStTeams environment; if you wish to join the OHDSI Teams environment, [please fill this form out](#). Once there, you can tell us [which working groups or studies](#) you would like to join.

Published Studies

Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Fišter K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, van der Leij J, Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostroplets A, Park RW, Prats-Urbe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto-Alhambra D; OHDSI-COVID-19 consortium. [Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study](#). *Lancet Rheumatol*. 2020 Nov;2(11):e698-e711. doi: 10.1016/S2665-9913(20)30276-9. Epub 2020 Aug 21. PMID: 32864627; PMCID: PMC7442425. [\[OHDSI press release\]](#)

Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahão MTF, Alberg A, Alghoul H, Alser O, Alshammari TM, Aragon M, Areia C, Banda JM, Cho J, Culhane AC, Davydov A, DeFalco FJ, Duarte-Salles T, DuVall S, Falconer T, Fernandez-Bertolin S, Gao W, Golozar A, Hardin J, Hripcsak G, Huser V, Jeon H, Jing Y, Jung CY, Kaas-Hansen BS, Kaduk D, Kent S, Kim Y, Kolovos S, Lane JCE, Lee H, Lynch KE, Makadia R, Matheny ME, Mehta PP, Morales DR, Natarajan K, Nyberg F, Ostroplets A, Park RW, Park J, Posada JD, Prats-Urbe A, Rao G, Reich C, Rho Y, Rijnbeek P, Schilling LM, Schuemie M, Shah NH, Shoaibi A, Song S, Spotnitz M, Suchard MA, Swerdel JN, Vizcaya D, Volpe S, Wen H, Williams AE, Yimer BB, Zhang L, Zhuk O, Prieto-Alhambra D, Ryan P. [Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study](#). *Nat Commun*. 2020 Oct 6;11(1):5009. doi: 10.1038/s41467-020-18849-z. PMID: 33024121; PMCID: PMC7538555. [\[OHDSI press release\]](#)

Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fernández-Bertolin S, Aragón M, DuVall SL, Lynch K, Falconer T, van Bochove K, Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Urbe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripcsak G, Suchard MA. [Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis](#). *Lancet Digit Health*. 2021 Feb;3(2):e98-e114. doi: 10.1016/S2589-7500(20)30289-2. Epub 2020 Dec 17. PMID: 33342753; PMCID: PMC7834915. [\[OHDSI press release\]](#)

Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Areia C, Biedermann P, Banda JM, Burn E, Casajust P, Fister K, Hardin J, Hester L, Hripcsak G, Kaas-Hansen BS, Khosla S, Kolovos S, Lynch KE, Makadia R, Mehta PP, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostroplets A, Woong Park R, Prats-Urbe A, Rao GA, Reich C, Rijnbeek P, Sena AG, Shoaibi A, Spotnitz M, Vignesh S, Suchard MA, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Lovestone S, Ryan P, Prieto-Alhambra D; OHDSI-COVID-19 consortium. [Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study](#). *Rheumatology (Oxford)*. 2020 Dec 25;kea771. doi: 10.1093/rheumatology/keaa771. Epub ahead of print. PMID: 33367863; PMCID: PMC7798671.

Reps JM, Kim C, Williams RD, Markus AF, Yang C, Salles TD, Falconer T, Jonnagaddala J, Williams A, Fernández-Bertolin S, DuVall SL, Kostka K, Rao G, Shoaibi A, Ostroplets A, Spotnitz ME, Zhang L, Casajust P, Steyerberg EW, Nyberg F, Kaas-Hansen BS, Choi YH, Morales D, Liaw ST, Abrahão MTF, Areia C, Matheny ME, Aragón M, Park RW, Hripcsak G, Reich CG, Suchard MA, You SC, Ryan PB, Prieto-Alhambra D, Rijnbeek PR. [Can we trust the prediction model? Illustrating the importance of external validation by implementing the COVID-19 Vulnerability \(C-19\) Index across an international network of observational healthcare datasets](#). *JMIR Med Inform*. 2021 Feb 27. doi: 10.2196/21547. Epub ahead of print. PMID: 33661754.

Tan EH, Sena AG, Prats-Urbe A, You SC, Ahmed WU, Kostka K, Reich C, DuVall SL, Lynch KE, Matheny ME, Duarte-Salles T, Bertolin SF, Hripcsak G, Natarajan K, Falconer T, Spotnitz M, Ostroplets A, Blacketer C, Alshammari TM, Alghoul H, Alser O, Lane JCE, Dawoud DM, Shah K, Yang Y, Zhang L, Areia C, Golozar A, Reicade M, Casajust P, Jonnagaddala J, Subbian V, Vizcaya D, Lai LY, Nyberg F, Morales DR, Posada JD, Shah NH, Gong M, Vivekanantham A, Abend A, Minty EP, Suchard M, Rijnbeek P, Ryan PB, Prieto-Alhambra D. [Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis](#). *Rheumatology (Oxford)*. 2021 Mar 16;keab250. doi: 10.1093/rheumatology/keab250. PMID: 33269355; PMCID: PMC7709171.

Shoaibi A, Fortin S, Weinstein R, Berlin J, Ryan, P. [Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients. The American Journal of Gastroenterology](#). 2021 Jan 28. doi: 10.14309/ajg.0000000000001153

Prats-Urbe A, Sena AG, Lai LY, Ahmed W, Alghoul H, Alser O, Alshammari TM, Areia C, Carter W, Casajust P, Dawoud D, Golozar A, Jonnagaddala J, Mehta P, Gong M, Morales DR, Nyberg F, Posada J, Recalde M, Roel E, Shah K, Shah NH, Schilling L, Subbian V, Vizcaya D, Zhang L, Zhang Y, Zhu H, Liu L, Cho J, You SC, Rijnbeek P, Hripcsak G, Lane JCE, Burn E, Reich C, Suchard M, Duarte-Salles T, Kostka K, Ryan PB, Prieto-Alhambra D. [Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study](#). *BMJ*. 373 2021; doi:10.1136/bmj.n1038. [\[OHDSI press release\]](#)

Duarte-Salles T, Vizcaya D, Pistillo A, Casajust P, Sena AG, Lai LY, Prats-Urbe A, Ahmed W, Alshammari TM, Alghoul H, Alser O, Burn E, You SC, Areia C, Blacketer C, Duval S, Falconer T, Carter W, Fernandez-Bertolin S, Fortin S, Golozar A, Gong M, Tan EH, Huser V, Iveli P, Morales DR, Nyberg F, Posada J, Recalde M, Roel E, Schilling L, Shah NH, Shah K, Suchard M, Zhang L, Zhang Y, Williams A, Reich C, Hripcsak G, Rijnbeek P, Ryan PB, Kostka K, Prieto-Alhambra D. [30-day outcomes of children and adolescents with COVID-19: an international experience](#). *Pediatrics*. 2021; doi: 10.1542/peds.2020-042929. [\[OHDSI press release\]](#)

Preprints

Prieto-Alhambra D, et al. [Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS](#). doi: 10.21203/rs.3.rs-279400/v1

Williams R, et al. [Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network](#). doi: 10.1101/2020.05.26.20112649

Recalde M, et al. [Characteristics and outcomes of 627,044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom](#). doi: 10.1101/2020.09.02.20185173

Prats-Urbe A, et al. [Heterogeneity and temporal variation in the management of COVID-19: a multinational drug utilization study including 71,921 hospitalized patients from China, South Korea, Spain, and the United States of America](#). doi: 10.1101/2020.09.15.20195545

Lai L, et al. [Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis](#). doi: 10.1101/2020.10.13.20211821

Roel E, et al. [Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain](#). doi: 10.1101/2021.01.12.21249672

Kohler J, et al. [Using Real World Data to Understand HIV and COVID-19 in the U.S.A. and Spain: Characterizing Co-Infected Patients Across the Care Cascade](#). doi: 10.1101/2020.11.10.20229401

Golozar A, et al. [Baseline phenotype and 30-day outcomes of people tested for COVID-19: an international network cohort including >3.32 million people tested with real-time PCR and >219,000 tested positive for SARS-CoV-2 in South Korea, Spain and the United States](#). doi: 10.1101/2020.10.25.20218875

Burn E, et al. [Use of dialysis, tracheostomy, and extracorporeal membrane oxygenation among 842,928 patients hospitalized with COVID-19 in the United States](#). doi: 10.1101/2020.11.25.20229088


Nishimuri A, et al. [Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients: an international cohort study](#). doi: 10.1101/2021.03.18.21253778



www.ohdsi.org/covid-19-updates



OHDSI Shoutouts!



Any shoutouts from the community? Please share and help promote and celebrate OHDSI work!

Have a study published? Please send to sachson@ohdsi.org so we can share during this call and on our social channels.
Let's work together to promote the collaborative work happening in OHDSI!





Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?





Upcoming Workgroup Calls



Date	Time (ET)	Meeting
Tuesday	1 pm	Common Data Model
Tuesday	3 pm	OMOP CDM Oncology – Outreach/Research Subgroup
Wednesday	8 am	Vaccine Vocabulary
Wednesday	11:30 am	Pharmacovigilance Evidence Investigation (PEI)
Wednesday	4 pm KST	Patient-Level Prediction/Population Level Estimation (Eastern Hemi)
Thursday	12 pm	Patient-Level Prediction/Population Level Estimation (Western Hemi)
Thursday	10 am	OMOP CDM Oncology – CDM/Vocabulary Subgroup
Monday	8 am	Early Stage Researchers (Europe/East Coast/West Coast)
Tuesday	9 am	OMOP CDM Oncology – Genomic Subgroup

www.ohdsi.org/upcoming-working-group-calls



Last Meeting: APAC 10-Minute Tutorials



White Rabbit

Xialin Wang



USAGI

Seng Chan You



Data Quality Dashboard

Selva Muthu Kumaran Sathappan

OHDSI APAC - Our Asia-Pacific Community

OHDSI is a global, multi-stakeholder, interdisciplinary and open-science network that collaborates to bring out the value of health data through large-scale analytics. Our Asia-Pacific (APAC) community comprises six regional chapters (Australia, China, Japan, Singapore, South Korea, Taiwan) and has led important OHDSI initiatives around the world.

The [first OHDSI APAC Symposium](#) was held virtually Dec. 5-6, 2020, and it provided an opportunity for our Asia-Pacific collaborators (along with others around the world) to share research, provide community updates, collaborate in regional breakouts or network discussions, and have some OHDSI fun.

The APAC community has its own group in the OHDSI MS Teams environment to promote greater collaboration on our collaborative efforts. It will also be the home of our bi-weekly APAC Community Calls, where we will provide updates, share research presentations, collaborate on topics of shared interest, and plenty more. How can you get involved? First, [request access to our MS Teams Environment](#), then request access to [our OHDSI APAC workgroup](#). You can also join the meetings [by using this direct link](#).

Our calls are scheduled on a bi-weekly basis, held every other Thursday/Wednesday depending on where you live. All calls are recorded, so if you miss one or want to share with a collaborator, check out the call recordings below.



Upcoming APAC Community Calls

Date	Topic
May 6	Collaborator Showcase Presentations
May 20	10-Minute Tutorials
June 3	Network Research
June 17	Welcome to OHDSI
July 1	OMOP Projects

[@OHDSI](#) [www.ohdsi.org](#) [#JoinTheJourney](#) [linkedin.com/company/ohdsi](#)

+ June 3, 2021 - APAC Network Research

— May 22, 2021 - 10-Minute Tutorials

Theme – 10-Minute Tutorials

www.ohdsi.org/apac/



Next APAC Community Call

The next APAC Community Call will be this Thursday/Wednesday, and the focus will be APAC Network Research.

Byungkon Kang: Automated terminology mapping via deep learning-based semantic matching

Ty Stanford: LEGEND Shiny app

The APAC Community Calls are held in MS Teams.

www.ohdsi.org/apac/

OHDSI APAC - Our Asia-Pacific Community

OHDSI is a global, multi-stakeholder, interdisciplinary and open-science network that collaborates to bring out the value of health data through large-scale analytics. Our Asia-Pacific (APAC) community comprises six regional chapters (Australia, China, Japan, Singapore, South Korea, Taiwan) and has led important OHDSI initiatives around the world.

The [first OHDSI APAC Symposium](#) was held virtually Dec. 5-6, 2020, and it provided an opportunity for our Asia-Pacific collaborators (along with others around the world) to share research, provide community updates, collaborate in regional breakouts or network discussions, and have some OHDSI fun.



Upcoming APAC Community Calls

Date	Topic
May 6	Collaborator Showcase Presentations
May 20	10-Minute Tutorials
June 3	Network Research
June 17	Welcome to OHDSI
July 1	OMOP Projects

[@OHDSI](#) www.ohdsi.org [#JoinTheJourney](#) linkedin.com/company/ohdsi

The APAC community has its own group in the OHDSI MS Teams environment to promote greater collaboration on our collaborative efforts. It will also be the home of our bi-weekly APAC Community Calls, where we will provide updates, share research presentations, collaborate on topics of shared interest, and plenty more. How can you get involved? First, [request access to our MS Teams Environment](#), then request access to [our OHDSI APAC workgroup](#). You can also join the meetings [by using this direct link](#).

Our calls are scheduled on a bi-weekly basis, held every other Thursday/Wednesday depending on where you live. All calls are recorded, so if you miss one or want to share with a collaborator, check out the call recordings below.

+ June 3, 2021 - APAC Network Research

— May 22, 2021 - 10-Minute Tutorials

Theme – 10-Minute Tutorials

Get Access To Different Teams/WGs/Chapters



The screenshot shows the OHDSI website with the navigation menu at the top. The 'Collaborate in MStTeams' link is highlighted with a red circle. Below the menu, the 'Join Work groups, Chapters, and Studies Registration' form is displayed. The form includes a section for '1. First and Last Name' with a required field. A red arrow points to the 'Join Work groups, Chapters, and Studies Registration' link in the navigation menu.

Welcome to OHDSI!

The Observational Health Data Sciences and Informatics (or OHDSI, pronounced 'oh-dsee') program is a multi-stakeholder collaborative to bring out the best through large-scale analytics. All teams are open-source.

OHDSI has established

OHDSI MStTeams Work groups, Chapters, and Studies Registration

OHDSI is using MStTeams to further encourage active collaboration within the community. Within the OHDSI organization, there are separate teams for work groups, chapters, and studies, as well as OHDSI community activities (such as the OHDSI2020 Symposium). All teams are open to all collaborators. Below please indicate which Team you would like to join and the OHDSI coordinating center team will grant access.

* Required

1. First and Last Name *

Enter your answer

4. Select the workgroups you want to join (you can refer to the WIKI for work group objectives www.ohdsi.org/web/wiki/doku.php?id=projects:overview)

- ☐ ATLAS
- ☐ Clinical Trials
- ☐ Common Data Model
- ☐ Data Quality Dashboard Development
- ☐ Early-stage Researchers
- ☐ Education Work Group
- ☐ Electronic Health Record (EHR) ETL
- ☐ Geographic Information System (GIS)
- ☐ HADES Health Analytics Data-to-Evidence Suite
- ☐ Latin America
- ☐ Medical Devices
- ☐ Natural Language Processing
- ☐ OHDSI APAC
- ☐ OHDSI APAC Steering Committee
- ☐ OHDSI Steering Committee
- ☐ Oncology
- ☐ Patient-Generated Health Data
- ☐ Pharmacovigilance Evidence Investigation

- ☐ Phenotype Development and Evaluation
- ☐ Population-Level Effect Estimation / Patient-Level Prediction
- ☐ Psychiatry
- ☐ Registry (formerly UK Biobank)
- ☐ Surgery and Perioperative Medicine
- ☐ Vaccine Vocabulary
- ☐ Women of OHDSI

5. Select the chapter(s) you want to join

- ☐ Australia
- ☐ China
- ☐ Europe
- ☐ Japan
- ☐ Korea
- ☐ Singapore
- ☐ Taiwan

6. Select the studies you want to join

- ☐ HERA-Health Equity Research Assessment
- ☐ PIONEER for Prostate Cancer (study-a-thon ended)
- ☐ SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses)



CBER Seminar Series


The next edition of the CBER BEST Initiative Seminar Series will be **Wednesday, June 16 (11 am)**. **Bruce Fireman** (Kaiser Permanente) will present a talk on “Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines.” The seminar series is open to everybody. More information and a registration link at the link below.



Webinar Registration



Topic	CBER BEST Initiative Seminar Series - Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines
Description	<p>Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines</p> <p>We review statistical methods used in observational studies of the safety and effectiveness of COVID-19 vaccines. Topics include:</p> <ul style="list-style-type: none">- How to compare recent vaccinees with concurrent comparators (unvaccinated or less recently vaccinated) and with comparators who are not concurrent (historical rates or self-controls) to make inferences about outcome rates that would be expected among vaccinees had they not been vaccinated.- Methods for estimating risk ratios- How to examine change in vaccine effectiveness (waning) or vaccine safety over time-since-vaccination- Sequential tests <p>Presented by: Bruce Fireman, MA - Kaiser Permanente</p>



https://northeastern.zoom.us/webinar/register/WN_94CygX5JTfSyhDSsOYnxqg



Job Opportunity

REGENERON CAREERS

Life at Regeneron

Locations

Entry Careers



Senior Manager, Clinical Informatics

Tarrytown, NY, United States • Research and Development • 24565BR

The Senior Manager Clinical Informatics will be responsible conducting analyses involving clinical and phenotypic data for genetics studies as well as clinical development and commercial programs. Responsibilities will include developing complex phenotypes as well as curating, cleaning, and analyzing large-scale phenotypic datasets, including de-identified EHR extracts from external collaborators, targeted clinical datasets in selected cohorts, and internal datasets from clinical trials and other human subject research.

A typical day may include:

- Conducting data analysis, including mining and curating of phenotypic datasets with primary responsibility in developing and identifying complex clinical phenotypes and cohorts of interest for “phenotype first” genomic analysis of associated samples and efficient data mining and association analysis in both phenotype first and genotype first queries.
- Developing complex phenotypes using advanced analytic approaches (i.e. machine learning, incorporating unstructured data sources using NLP, etc.)
- Collaboration and coordination with external health system collaborators and informatics teams mining EHR and phenotypic data sets. Work with these collaborators to structure data and develop algorithms, rules engines, and querying tools to access and curate the phenotypic datasets.
- Functioning as a subject matter expert in quantitative analysis techniques
- Representing the RGC at external meetings; providing scientific and strategic input to the group



Collaborator Showcase Abstracts Due June 18

We are **17 DAYS AWAY** from the **June 18 deadline** for submissions for the 2021 Collaborator Showcase.

We are accepting submissions for posters, oral presentations and software demos.

OHDSI

2021 OHDSI Collaborators Showcase Brief Report Submission Form- Posters, Oral Talks and Software Demonstrations

Thank you for your interest in the 2021 OHDSI Collaborators Showcase! We are delighted that you are interested in showcasing your work at this year's virtual symposium showcase. For planning purposes, please take a few minutes to fill out this submission form to help the Scientific Review Committee better understand your solution.

By filling out this form you may choose if you would like to present your work as a poster, an oral talk or a software demonstration (or all three). If a poster or software demo, you will present it during the Collaborator Showcase at the symposium. If an Oral talk, you will present an estimated 7-minute talk at the symposium.

If you wish to present as a poster or an oral talk only, after you complete that question below the form will skip you to the section to upload your brief report. If you wish to present as a software demo only or also with a poster and/or oral talk, after you answer that question below, you will complete several questions on the software demo. You will then be asked to submit a one-page overview of your software. If you want to submit for all three (software demo, poster and/or oral talk), it will then ask you to submit a brief report for the poster and/or oral submission.

Although we strive to accommodate your requested presentation format, it is not guaranteed. If the review committee has selected your work to be presented at this year's showcase, you will be notified via email by August 2, 2021 and the presentation format will be confirmed at that time.

Topics should align with at least one of OHDSI's strategic areas of focus:

- Observational data standards and management
- Open-source analytics development
- Methodological research
- Clinical applications

SUBMISSION INSTRUCTIONS:

A brief report submission template can be found by using the below link:
https://docs.google.com/document/d/1GADPitvH1eXHX_W9qBOlg-nv2gAVnloH2c7kCgtWGqk/edit?usp=sharing

The document can be downloaded as a Microsoft Word document by clicking on the link and selecting File->Download As...-> Microsoft Word (.docx).



Where Are We Going?

**Any other announcements
of upcoming work, events,
deadlines, etc?**





Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?

